Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DWP14012 vs DWC202301 triple therapy for H. pylori eradication
NCT06751121Phase 3Completed
- Sponsor
- Daewoong Pharmaceutical
- Start
- Feb 2024
- Primary completion
- Apr 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fexuprazan in Helicobacter pylori infection, sponsored by Daewoong Pharmaceutical. Started Feb 2024; status: completed.
02
Drugs
fexuprazan
03
Conditions
Helicobacter pylori infection
Beyond the preview
Go deeper on NCT06751121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06751121.